Which has stronger earnings and valuation, SNN or ATRC?

Smith & Nephew SNATS has higher revenue and earnings than AtriCure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 1.84 $625M N/A N/A AtriCure $534.53M 5.03 -$11.45M $0.21 251.62

Does the media refer more to SNN or ATRC?

In the previous week, AtriCure had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 4 mentions for AtriCure and 3 mentions for Smith & Nephew SNATS. AtriCure's average media sentiment score of 0.22 beat Smith & Nephew SNATS's score of -0.21 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ATRC or GMED?

Globus Medical has higher revenue and earnings than AtriCure. Globus Medical is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.03 -$11.45M $0.21 251.62 Globus Medical $2.94B 3.35 $537.87M $3.91 18.76

Does the media prefer ATRC or GMED?

In the previous week, Globus Medical had 1 more articles in the media than AtriCure. MarketBeat recorded 5 mentions for Globus Medical and 4 mentions for AtriCure. Globus Medical's average media sentiment score of 0.28 beat AtriCure's score of 0.22 indicating that Globus Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Globus Medical 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ATRC or GKOS?

AtriCure has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.03 -$11.45M $0.21 251.62 Glaukos $507.44M 18.69 -$187.69M -$3.25 N/A

Is ATRC or GKOS more profitable?

AtriCure has a net margin of 1.85% compared to Glaukos' net margin of -30.68%. AtriCure's return on equity of 2.34% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Glaukos -30.68% -6.37% -4.78%

Does the media prefer ATRC or GKOS?

In the previous week, Glaukos had 11 more articles in the media than AtriCure. MarketBeat recorded 15 mentions for Glaukos and 4 mentions for AtriCure. Glaukos' average media sentiment score of 0.49 beat AtriCure's score of 0.22 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, PODD or ATRC?

Insulet has higher revenue and earnings than AtriCure. Insulet is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.44 $247.10M $5.35 25.13 AtriCure $534.53M 5.03 -$11.45M $0.21 251.62

Is PODD or ATRC more profitable?

Insulet has a net margin of 12.29% compared to AtriCure's net margin of 1.85%. Insulet's return on equity of 29.29% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% AtriCure 1.85% 2.34% 1.77%

Does the media prefer PODD or ATRC?

In the previous week, Insulet and Insulet both had 4 articles in the media. AtriCure's average media sentiment score of 0.22 beat Insulet's score of 0.00 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MMED or ATRC?

In the previous week, MiniMed Group had 5 more articles in the media than AtriCure. MarketBeat recorded 9 mentions for MiniMed Group and 4 mentions for AtriCure. MiniMed Group's average media sentiment score of 0.37 beat AtriCure's score of 0.22 indicating that MiniMed Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AtriCure (ATRC) Competitors

$52.84 -0.47 (-0.88%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$53.50 +0.66 (+1.25%)

As of 08:10 AM Eastern

Compare

ATRC vs. SNN, GMED, GKOS, PODD, and MMED

Should you buy AtriCure stock or one of its competitors? AtriCure's main competitors and comparable companies include Smith & Nephew SNATS (SNN), Globus Medical (GMED), Glaukos (GKOS), Insulet (PODD), and MiniMed Group (MMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does AtriCure compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Smith & Nephew SNATS has higher revenue and earnings than AtriCure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	1.84	$625M	N/A	N/A
AtriCure	$534.53M	5.03	-$11.45M	$0.21	251.62

Smith & Nephew SNATS currently has a consensus price target of $31.91, indicating a potential upside of 18.43%. AtriCure has a consensus price target of $53.30, indicating a potential upside of 0.87%. Given Smith & Nephew SNATS's higher probable upside, research analysts clearly believe Smith & Nephew SNATS is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

AtriCure has a net margin of 1.85% compared to Smith & Nephew SNATS's net margin of 0.00%. AtriCure's return on equity of 2.34% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
AtriCure	1.85%	2.34%	1.77%

Smith & Nephew SNATS has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, AtriCure had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 4 mentions for AtriCure and 3 mentions for Smith & Nephew SNATS. AtriCure's average media sentiment score of 0.22 beat Smith & Nephew SNATS's score of -0.21 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AtriCure beats Smith & Nephew SNATS on 11 of the 14 factors compared between the two stocks.

How does AtriCure compare to Globus Medical?

AtriCure (NASDAQ:ATRC) and Globus Medical (NYSE:GMED) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

AtriCure currently has a consensus price target of $53.30, indicating a potential upside of 0.87%. Globus Medical has a consensus price target of $99.46, indicating a potential upside of 35.58%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts clearly believe Globus Medical is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88

Globus Medical has a net margin of 17.02% compared to AtriCure's net margin of 1.85%. Globus Medical's return on equity of 14.57% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Globus Medical	17.02%	14.57%	12.62%

In the previous week, Globus Medical had 1 more articles in the media than AtriCure. MarketBeat recorded 5 mentions for Globus Medical and 4 mentions for AtriCure. Globus Medical's average media sentiment score of 0.28 beat AtriCure's score of 0.22 indicating that Globus Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Globus Medical	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Globus Medical has higher revenue and earnings than AtriCure. Globus Medical is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.03	-$11.45M	$0.21	251.62
Globus Medical	$2.94B	3.35	$537.87M	$3.91	18.76

AtriCure has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Globus Medical beats AtriCure on 13 of the 17 factors compared between the two stocks.

How does AtriCure compare to Glaukos?

AtriCure (NASDAQ:ATRC) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

AtriCure has a net margin of 1.85% compared to Glaukos' net margin of -30.68%. AtriCure's return on equity of 2.34% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Glaukos	-30.68%	-6.37%	-4.78%

99.1% of AtriCure shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AtriCure has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

AtriCure has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.03	-$11.45M	$0.21	251.62
Glaukos	$507.44M	18.69	-$187.69M	-$3.25	N/A

In the previous week, Glaukos had 11 more articles in the media than AtriCure. MarketBeat recorded 15 mentions for Glaukos and 4 mentions for AtriCure. Glaukos' average media sentiment score of 0.49 beat AtriCure's score of 0.22 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AtriCure presently has a consensus price target of $53.30, suggesting a potential upside of 0.87%. Glaukos has a consensus price target of $180.54, suggesting a potential upside of 12.25%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

AtriCure beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does AtriCure compare to Insulet?

Insulet (NASDAQ:PODD) and AtriCure (NASDAQ:ATRC) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

99.1% of AtriCure shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Insulet and Insulet both had 4 articles in the media. AtriCure's average media sentiment score of 0.22 beat Insulet's score of 0.00 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insulet has higher revenue and earnings than AtriCure. Insulet is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.44	$247.10M	$5.35	25.13
AtriCure	$534.53M	5.03	-$11.45M	$0.21	251.62

Insulet currently has a consensus target price of $193.48, suggesting a potential upside of 43.88%. AtriCure has a consensus target price of $53.30, suggesting a potential upside of 0.87%. Given Insulet's higher probable upside, analysts plainly believe Insulet is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	12 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.46
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Insulet has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Insulet has a net margin of 12.29% compared to AtriCure's net margin of 1.85%. Insulet's return on equity of 29.29% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
AtriCure	1.85%	2.34%	1.77%

Summary

Insulet beats AtriCure on 8 of the 15 factors compared between the two stocks.

How does AtriCure compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and AtriCure (NASDAQ:ATRC) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

99.1% of AtriCure shares are held by institutional investors. 0.0% of MiniMed Group shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AtriCure has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.80	-$333M	-$0.68	N/A
AtriCure	$534.53M	5.03	-$11.45M	$0.21	251.62

AtriCure has a net margin of 1.85% compared to MiniMed Group's net margin of 0.00%. AtriCure's return on equity of 2.34% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
AtriCure	1.85%	2.34%	1.77%

MiniMed Group presently has a consensus price target of $24.00, suggesting a potential upside of 21.21%. AtriCure has a consensus price target of $53.30, suggesting a potential upside of 0.87%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiniMed Group is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, MiniMed Group had 5 more articles in the media than AtriCure. MarketBeat recorded 9 mentions for MiniMed Group and 4 mentions for AtriCure. MiniMed Group's average media sentiment score of 0.37 beat AtriCure's score of 0.22 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AtriCure beats MiniMed Group on 9 of the 15 factors compared between the two stocks.

Get AtriCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRC vs. The Competition

Export

Metric	AtriCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.71B	$5.44B	$7.19B	$13.37B
Dividend Yield	N/A	1.78%	2.53%	16.36%
P/E Ratio	251.63	25.26	274.66	26.04
Price / Sales	5.03	68.53	568.58	76.65
Price / Cash	170.32	32.10	76.82	53.72
Price / Book	5.34	5.88	10.88	6.27
Net Income	-$11.45M	$146.72M	$3.50B	$382.01M
7 Day Performance	-4.17%	-0.83%	-1.84%	-1.60%
1 Month Performance	-0.36%	-3.80%	-6.36%	-4.63%
1 Year Performance	44.89%	1.79%	3.07%	-0.95%

AtriCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRC AtriCure	2.6561 of 5 stars	$52.84 -0.9%	$53.30 +0.9%	+50.6%	$2.71B	$534.53M	251.63	1,350
SNN Smith & Nephew SNATS	3.3219 of 5 stars	$26.79 -1.1%	$31.91 +19.1%	-25.0%	$11.25B	$6.16B	N/A	16,988
GMED Globus Medical	4.0849 of 5 stars	$75.31 +0.7%	$101.77 +35.1%	+21.3%	$10.11B	$2.94B	19.25	6,000
GKOS Glaukos	2.392 of 5 stars	$157.61 -0.6%	$180.54 +14.6%	+83.7%	$9.30B	$507.44M	N/A	1,094	Trending News
PODD Insulet	4.3139 of 5 stars	$131.42 -1.3%	$195.40 +48.7%	-57.4%	$9.12B	$2.71B	24.58	5,400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRC) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AtriCure (ATRC) Competitors

ATRC vs. SNN, GMED, GKOS, PODD, and MMED

How does AtriCure compare to Smith & Nephew SNATS?

Summary

How does AtriCure compare to Globus Medical?

Summary

How does AtriCure compare to Glaukos?

Summary

How does AtriCure compare to Insulet?

Summary

How does AtriCure compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRC vs. The Competition

AtriCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AtriCure (ATRC) Competitors

ATRC vs. SNN, GMED, GKOS, PODD, and MMED

How does AtriCure compare to Smith & Nephew SNATS?

Which has stronger earnings and valuation, SNN or ATRC?

Do analysts recommend SNN or ATRC?

Is SNN or ATRC more profitable?

Which has more volatility and risk, SNN or ATRC?

Do institutionals and insiders have more ownership in SNN or ATRC?

Does the media refer more to SNN or ATRC?

Summary

How does AtriCure compare to Globus Medical?

Do analysts rate ATRC or GMED?

Is ATRC or GMED more profitable?

Does the media prefer ATRC or GMED?

Which has stronger earnings and valuation, ATRC or GMED?

Which has more risk & volatility, ATRC or GMED?

Do insiders & institutionals have more ownership in ATRC or GMED?

Summary

How does AtriCure compare to Glaukos?

Is ATRC or GKOS more profitable?

Do institutionals & insiders believe in ATRC or GKOS?

Which has more risk and volatility, ATRC or GKOS?

Which has better earnings and valuation, ATRC or GKOS?

Does the media prefer ATRC or GKOS?

Do analysts rate ATRC or GKOS?

Summary

How does AtriCure compare to Insulet?

Do insiders & institutionals believe in PODD or ATRC?

Does the media prefer PODD or ATRC?

Which has higher valuation and earnings, PODD or ATRC?

Do analysts rate PODD or ATRC?

Which has more volatility and risk, PODD or ATRC?

Is PODD or ATRC more profitable?

Summary

How does AtriCure compare to MiniMed Group?

Do insiders and institutionals hold more shares of MMED or ATRC?

Which has better valuation & earnings, MMED or ATRC?

Is MMED or ATRC more profitable?

Do analysts prefer MMED or ATRC?

Does the media refer more to MMED or ATRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRC vs. The Competition

AtriCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools